OXFORD, England & PASADENA, Calif.– Rockley Photonics Holdings Limited (NYSE: RKLY) (“the Company” or “Rockley”), a global leader in photonics-based health monitoring and communications solutions, today announced that it has agreed to enter a development partnership with Medtronic, a global leader in healthcare technology. The two companies plan to collaborate to bring Rockley’s recently announced Bioptx™ biomarker sensing platform into Medtronic’s solutions for use across various healthcare settings.
Rockley’s biosensing technology is expected to expand the capabilities of wearable medtech devices by miniaturizing the measurement and analysis of a range of biomarkers into a compact form factor. These advances mean that a single wearable device could monitor multiple crucial biomarkers – including core body temperature, blood pressure, body hydration, alcohol, lactate, and glucose trends, among others. The Bioptx platform offers an end-to-end sensing solution that integrates cloud analytics and artificial intelligence (AI) to potentially deliver a holistic assessment of a variety of conditions.
The partnership with Medtronic builds on the societal shift from reactive to proactive healthcare by potentially enabling round-the-clock, real-time, non-invasive monitoring of a person’s health and well-being, thereby empowering clinicians to personalize care with actionable data.
Dr. Andrew Rickman, chairman and chief executive officer of Rockley, said, “This partnership combines Medtronic’s exceptional strength in providing in-patient care with Rockley’s expertise in wearable, remote monitoring. I believe that this collaboration will bring to life our vision of giving people better insights into their health and well-being. We are excited about the potential for this partnership to herald the next generation of wearable devices and deliver a complete lifecycle of patient care.” (IANS)
